91,793 Shares in Horizon Pharma PLC (HZNP) Purchased by Sterling Capital Management LLC

Sterling Capital Management LLC acquired a new stake in shares of Horizon Pharma PLC (NASDAQ:HZNP) in the fourth quarter, HoldingsChannel.com reports. The fund acquired 91,793 shares of the biopharmaceutical company’s stock, valued at approximately $1,340,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Sei Investments Co. boosted its position in Horizon Pharma by 68.5% during the third quarter. Sei Investments Co. now owns 391,170 shares of the biopharmaceutical company’s stock valued at $4,961,000 after purchasing an additional 159,002 shares during the last quarter. American International Group Inc. boosted its position in Horizon Pharma by 8.1% during the third quarter. American International Group Inc. now owns 109,477 shares of the biopharmaceutical company’s stock valued at $1,388,000 after purchasing an additional 8,185 shares during the last quarter. Wells Fargo & Company MN boosted its position in Horizon Pharma by 24.8% during the third quarter. Wells Fargo & Company MN now owns 456,169 shares of the biopharmaceutical company’s stock valued at $5,784,000 after purchasing an additional 90,692 shares during the last quarter. Prudential Financial Inc. boosted its position in Horizon Pharma by 342.0% during the third quarter. Prudential Financial Inc. now owns 77,390 shares of the biopharmaceutical company’s stock valued at $981,000 after purchasing an additional 59,880 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its position in Horizon Pharma by 18.6% during the third quarter. Dimensional Fund Advisors LP now owns 7,433,330 shares of the biopharmaceutical company’s stock valued at $94,254,000 after purchasing an additional 1,167,722 shares during the last quarter. 86.75% of the stock is owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

A number of analysts recently issued reports on the company. ValuEngine cut Horizon Pharma from a “buy” rating to a “hold” rating in a research report on Tuesday, March 13th. Cantor Fitzgerald reissued a “buy” rating and set a $17.00 price objective on shares of Horizon Pharma in a research report on Wednesday, March 14th. Piper Jaffray reissued a “buy” rating and set a $22.00 price objective on shares of Horizon Pharma in a research report on Thursday, March 1st. Cowen reissued a “buy” rating and set a $24.00 price objective on shares of Horizon Pharma in a research report on Thursday, March 1st. Finally, UBS set a $20.00 price objective on Horizon Pharma and gave the company a “buy” rating in a research report on Thursday, March 1st. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $18.64.

Shares of Horizon Pharma PLC (NASDAQ HZNP) opened at $13.86 on Monday. Horizon Pharma PLC has a 12-month low of $9.45 and a 12-month high of $16.02. The firm has a market capitalization of $2,280.94, a PE ratio of -5.50, a price-to-earnings-growth ratio of 0.59 and a beta of 1.34. The company has a debt-to-equity ratio of 1.91, a current ratio of 1.63 and a quick ratio of 1.54.

Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.07. Horizon Pharma had a positive return on equity of 18.44% and a negative net margin of 38.87%. The company had revenue of $274.22 million during the quarter, compared to analysts’ expectations of $264.48 million. During the same quarter in the previous year, the firm earned $0.64 earnings per share. The business’s quarterly revenue was down 11.6% compared to the same quarter last year. sell-side analysts expect that Horizon Pharma PLC will post 1.43 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “91,793 Shares in Horizon Pharma PLC (HZNP) Purchased by Sterling Capital Management LLC” was published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3301892/91793-shares-in-horizon-pharma-plc-hznp-purchased-by-sterling-capital-management-llc.html.

Horizon Pharma Company Profile

Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.

Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).

Institutional Ownership by Quarter for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Intuit  Reaches New 1-Year High and Low at $182.93
Intuit Reaches New 1-Year High and Low at $182.93
Mitel Networks  Hits New 12-Month High and Low at $11.31
Mitel Networks Hits New 12-Month High and Low at $11.31
SodaStream  Reaches New 12-Month High and Low at $98.26
SodaStream Reaches New 12-Month High and Low at $98.26
$262.66 Million in Sales Expected for Voya Financial  This Quarter
$262.66 Million in Sales Expected for Voya Financial This Quarter
Zacks: Analysts Expect ICF  Will Post Quarterly Sales of $304.14 Million
Zacks: Analysts Expect ICF Will Post Quarterly Sales of $304.14 Million
American Ecology Co.  Expected to Post Quarterly Sales of $114.50 Million
American Ecology Co. Expected to Post Quarterly Sales of $114.50 Million


© 2006-2018 Ticker Report. Google+.